Edition:
United Kingdom

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

82.25NOK
19 Jan 2018
Change (% chg)

kr1.60 (+1.98%)
Prev Close
kr80.65
Open
kr80.65
Day's High
kr82.35
Day's Low
kr79.05
Volume
188,953
Avg. Vol
228,193
52-wk High
kr113.00
52-wk Low
kr66.40

Chart for

About

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide... (more)

Overall

Beta: --
Market Cap(Mil.): kr4,031.45
Shares Outstanding(Mil.): 49.04
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Nordic Nanovector presents updated results

* BETALUTIN® SHOWS STRONG CLINICAL PROFILE IN RELAPSED/REFRACTORY INDOLENT NHL AND FOLLICULAR LYMPHOMA

11 Dec 2017

BRIEF-Nordic Nanovector Q3 comprehensive loss widens to NOK 85.9 mln​

* ‍REVENUES FOR Q3 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)​

22 Nov 2017

BRIEF-Nordic Nanovector provides results from phase 1/2 study of Betalutinwill

* RESULTS FROM LYMRIT 37-01 PHASE 1/2 STUDY OF BETALUTINWILL BE PRESENTED IN A POSTER AT 59TH ANNUAL ASH MEETING​

01 Nov 2017

BRIEF-Nordic Nanovector Q2 comprehensive widens to NOK 66.3 mln

* REVENUES FOR Q2 AMOUNTED TO NOK 0.1 MILLION (NOK 0.1 MILLION)

23 Aug 2017

BRIEF-Nordic Nanovector to present at Wedbush PacGrow Healthcare Conference ​

* ‍COMPANY WILL BE PRESENTING AT WEDBUSH PACGROW HEALTHCARE CONFERENCE ON 15-16 AUGUST IN NEW YORK.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

10 Aug 2017

Earnings vs. Estimates